Community/Retail

Following the success of the phase 3 EMERGENT-2 trial, researchers suggest that xanomeline-trospium could be a safe and effective treatment option for adults with schizophrenia.

The biosimilar matches Prolia in efficacy, immunogenicity, pharmacodynamics, and pharmacokinetics in women who are postmenopausal with osteoporosis.

How would you respond to these patient questions?

Effective use of clinical reasoning might indeed be one of the major driving forces behind practice change toward more patient-centric care.

Pharmacist education also helps prevent adverse reactions, maximizes outcomes for the symptomless disease.

After 4 years, the 1-time cost of valoctocogene roxaparvovec appeared to be more cost-effective than the annual cost of emicizumab prophylaxis for hemophilia A, according to a new Draft Evidence Report.

Janssen’s GUIDE data demonstrate that patients treated with guselkumab less than 2 years after disease onset vs later are more likely to achieve “super-responder” at week 20 through 28.

Pivotal top-line data demonstrate 20vPnC, if approved likely protects against 20 serotypes in 3-dose series and may offer the broadest serotype coverage of any PCV.

Assess for medication-related problems, monitor patients remotely, and use mobile tools to deliver consultations.

On this month's episode hosts Jeremy Sasser and Jessica Langley-Loep from the National Healthcareer Association welcome their guest Christine Cline-Dahlman, BFA, CPhT, the founder and owner of PharmTechForward.

There are several important policy issues that could impact pharmacists’ ability to positively affect the quality of care for patients through the use of pharmacy performance measures.

Changing one’s diet could change brain health and study results suggest the Mediterranean diet could positively support cognitive function.

New research suggests that 200 g/day of milk can reduce the risk of type 2 diabetes by 10%.

Amendments reflecting more contemporary options could raise ethical questions for health care workers.

Research suggests cannabis can improve quality of life for patients who suffer from pain and neurological disorders.

Researchers will submit a new drug application to the FDA after a phase 3 trial found that iDose TR slow- and fast-release models met their primary endpoint in patients with glaucoma.

Pharmacists should get involved in all the various aspects of their business and with the different professional groups available.

GENDER R25 will provide funding for courses and curricula to improve gender-focused education and equity in pharmacy, as well as other health care fields.

The most important thing you must do is listen to the patient, understand their concerns, and by doing that, you will gain their trust to be able to treat them appropriately.

Pharmacists can educate older adults on risk factors and prevention efforts around herpes zoster.

Analytics allow for a better understanding of the needs of various patient populations and the barriers they face in accessing care.

USC Analysis: although generics save US health care systems billions, PBMs jack up prices for employers, government, and patients.

Quadrivalent mRNA influenza vaccine candidate to be evaluated in approximately 25,000 healthy US adults.

Migraines are multifactorial and patient-specific, causing accessible care and treatments to be limited and ignored.

Men with chronically low testosterone levels are more likely to be hospitalized from COVID-19 than those with normal levels, but testosterone therapy could decrease this risk.

Online communities can help opioid users in remission maintain long-lasting sobriety, however the research suggests these communities should be non-drug-related.

Care Coach program offers a comprehensive set of pharmacy and counseling services to patients struggling to manage their diabetes.

Simple steps to minimize risk are easily overlooked when pharmacies get busy.

Many drugs for these conditions enter clinical trials, but few demonstrate success.

DaxibotulinumtoxinA-lanm from Revance Therapeutics Inc is the first peptide-formulated neuromodulator with long-lasting results.